Bank of New York Mellon Corp Boosts Position in Genmab A/S (NASDAQ:GMAB)

Bank of New York Mellon Corp grew its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 71,623 shares of the company’s stock after buying an additional 2,749 shares during the period. Bank of New York Mellon Corp’s holdings in Genmab A/S were worth $1,495,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its holdings in Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after purchasing an additional 12,654 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of Genmab A/S in the 3rd quarter worth about $273,000. Verition Fund Management LLC bought a new position in shares of Genmab A/S in the 3rd quarter worth about $709,000. FMR LLC lifted its position in Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after acquiring an additional 33,076 shares during the period. Finally, Natixis Advisors LLC boosted its stake in Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after acquiring an additional 47,437 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Down 0.4 %

Shares of GMAB opened at $19.76 on Friday. The company has a market cap of $13.08 billion, a price-to-earnings ratio of 11.36, a P/E/G ratio of 2.65 and a beta of 0.98. The business’s fifty day simple moving average is $21.04 and its two-hundred day simple moving average is $22.15. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.02.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, research analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.